

Officer of the Assignee, Antex Biologics, Inc., depositor of the microorganisms (Jackson Declaration) with attached Exhibit A, and (4) a Supplemental Information Disclosure Statement with PTO-1449 Form and references AQ to BH.

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 12, beginning at line 22, replace the two paragraphs beginning "Figure 3...49143", with the following:

Figure 3. Determined nucleic acid sequence of OMP21 from *M. catarrhalis* strain 49143 SEQ ID NO.: 6.

Figure 4. Deduced Amino Acid Sequence of OMP21 from *M. catarrhalis* strain 49143 SEQ ID NO.: 7.

At page 25, replace the paragraph beginning "In other embodiments", at line 1, with the following:

In other embodiments, a peptide fragment of OMP21 is used as a n immunogen. Preferably, a peptide fragment of purified OMP21 or a chemically synthesized peptide fragment of OMP21 is used. The peptides may be produced by protease digestion, chemical cleavage of isolated or purified OMP21 or chemical synthesis and then may be isolated or purified. Such isolated or purified peptides can be used directly as immunogens. In particular embodiments, useful peptide fragments include but are not limited to those having the sequence AISYGN SADAQPYVGAKIGQVDAKQINGKNTAYGIYAGYN (SEQ ID NO.: 1) or any portion thereof that is 6 or more amino acids in length. In an another embodiment, the peptide has the sequence as shown in Figure 4 (SEQ ID NO.: 7).